1. Home
  2. MFA vs AVXL Comparison

MFA vs AVXL Comparison

Compare MFA & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MFA
  • AVXL
  • Stock Information
  • Founded
  • MFA 1997
  • AVXL 2004
  • Country
  • MFA United States
  • AVXL United States
  • Employees
  • MFA N/A
  • AVXL N/A
  • Industry
  • MFA Real Estate Investment Trusts
  • AVXL Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • MFA Real Estate
  • AVXL Health Care
  • Exchange
  • MFA Nasdaq
  • AVXL Nasdaq
  • Market Cap
  • MFA 980.3M
  • AVXL 794.0M
  • IPO Year
  • MFA N/A
  • AVXL N/A
  • Fundamental
  • Price
  • MFA $9.36
  • AVXL $11.01
  • Analyst Decision
  • MFA Buy
  • AVXL Strong Buy
  • Analyst Count
  • MFA 8
  • AVXL 2
  • Target Price
  • MFA $11.86
  • AVXL $44.00
  • AVG Volume (30 Days)
  • MFA 1.5M
  • AVXL 998.6K
  • Earning Date
  • MFA 08-06-2025
  • AVXL 08-05-2025
  • Dividend Yield
  • MFA 15.38%
  • AVXL N/A
  • EPS Growth
  • MFA N/A
  • AVXL N/A
  • EPS
  • MFA 0.99
  • AVXL N/A
  • Revenue
  • MFA $292,245,000.00
  • AVXL N/A
  • Revenue This Year
  • MFA N/A
  • AVXL N/A
  • Revenue Next Year
  • MFA $14.73
  • AVXL N/A
  • P/E Ratio
  • MFA $9.45
  • AVXL N/A
  • Revenue Growth
  • MFA 52.95
  • AVXL N/A
  • 52 Week Low
  • MFA $7.85
  • AVXL $4.60
  • 52 Week High
  • MFA $13.45
  • AVXL $14.44
  • Technical
  • Relative Strength Index (RSI)
  • MFA 42.80
  • AVXL 69.12
  • Support Level
  • MFA $9.51
  • AVXL $9.91
  • Resistance Level
  • MFA $9.73
  • AVXL $11.19
  • Average True Range (ATR)
  • MFA 0.19
  • AVXL 0.59
  • MACD
  • MFA -0.02
  • AVXL 0.15
  • Stochastic Oscillator
  • MFA 17.27
  • AVXL 94.69

About MFA MFA Financial Inc.

MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets and Lima One.

About AVXL Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.

Share on Social Networks: